NCT03492489No Longer Available不适用
An Open-Label, Expanded Access Protocol of Cemiplimab in Patients With Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma Who Are Not Candidates for Surgery
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
The objective of this program is to provide access to cemiplimab (REGN2810) to patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC) who are not candidates for surgery prior to cemiplimab (REGN2810) being commercially available.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of invasive Cutaneous Squamous Cell Carcinoma (CSCC)
- •Hepatic function:
- •Total bilirubin ≤1.5 x upper limit of normal (ULN; if liver metastases ≤3 x ULN).
- •Transaminases ≤3 x ULN (or ≤5.0 x ULN, if liver metastases)
- •Alkaline phosphatase ≤2.5 x ULN (or ≤5.0 x ULN, if liver or bone metastases) Patients with hepatic metastases: If transaminase levels (AST and/or ALT) are >3 x but ≤5 x ULN, total bilirubin must be ≤1.5 x ULN. If total bilirubin is >1.5 x but ≤3 x ULN, both transaminases (AST and ALT) must be ≤3 x ULN
- •Renal function: serum creatinine ≤1.5 x ULN or estimated creatinine clearance (CrCl) >30 mL/min
- •Bone marrow function:
- •Hemoglobin ≥9.0 g/dL
- •Absolute neutrophil count (ANC) ≥1.5 x 10^9/L
- •Platelet count ≥75 x 10^9/L
- •Patients not candidates for surgery include the examples below, but are not limited to:
- •Metastatic disease (distant or nodal)
- •Recurrence in the same location and curative resection is unlikely
- •Significant local invasion that precludes complete resection
- •Surgery may result in severe disfiguration or dysfunction
- •Other conditions deemed to be contraindicating for surgery
排除标准
- •Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events (irAEs). The following are not exclusionary: vitiligo, childhood asthma that has resolved, type 1 diabetes, residual hypothyroidism that required only hormone replacement, or psoriasis that does not require systemic treatment
- •Prior treatment with other immune modulating agents that was (a) within fewer than 4 weeks (28 days) prior to the first dose of cemiplimab (REGN2810), or (b) associated with immune-mediated adverse events (AEs) that were ≥ Grade 1 within 90 days prior to the first dose of cemiplimab (REGN2810), or (c) associated with toxicity that resulted in discontinuation of the immune-modulating agent
- •Continuous immunosuppressive corticosteroid treatment (doses >10 mg prednisone daily or equivalent) within 2 weeks prior to the first dose of cemiplimab (REGN2810)Note: Patients who require brief course of steroids (eg, as prophylaxis for imaging studies) are not excluded
- •Active uncontrolled infection requiring therapy, including infection with human immunodeficiency virus, or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
- •History of pneumonitis within the last 5 years
- •Note: Other protocol defined Inclusion/Exclusion criteria may apply
研究者
相似试验
Unknown
不适用
Expanded Access Use of Cemiplimab in Patients With Solid TumorsNCT06132191Regeneron Pharmaceuticals
Approved For Marketing
不适用
An Expanded Access Program of Emicizumab in Participants With Hemophilia A With InhibitorsHemophilia ANCT03154437Genentech, Inc.
Unknown
不适用
Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing EnteropathyCD55-Deficient Protein-Losing EnteropathyNCT06003881Regeneron Pharmaceuticals
No Longer Available
不适用
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple SclerosisMultiple SclerosisNCT02807285Genentech, Inc.
Unknown
不适用
Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal HemoglobinuriaNCT06028594Regeneron Pharmaceuticals